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Maria RescignoAbstract
Cancer immunotherapy is very effective and leads to
a long-term response in certain patients. Yet, the
variability observed in this response indicates that
additional factors related to the host must influence
the activity of the treatments. Recent research
suggests that the microbiota might play an important
part in this variability.cacy of ICI treatment is dependent on the host micro-
biota. Indeed, in mice reared under germ-free conditionsLinking the microbiota and immunotherapy
One observation that puzzles researchers is why the
same tumor cell line injected into genetically identical
mice gives rise to highly variable tumors. Why these
tumors respond differently to therapy is also not clear.
What is the difference between individual mice consider-
ing that their genome is identical? Two recent articles
published in Science [1, 2] show that this difference can
be attributed to the microbiota.
The microbiota is the community of microorganisms
that inhabit all the surfaces in an organism that are
exposed to the external environment, including the gut.
The microbiota is involved in several host functions,
including digestion of complex food macromolecules,
behavior and the development of the immune system
[3]. The microbiome (which is the genome of the micro-
biota) is 100 times larger than the human genome, and
thus contributes a huge quantity of additional, acquired
proteins and enzymes [4]. The microbiota is inherited
from mothers during delivery and lactation and is subse-
quently shaped by diet and environmental factors [5, 6].
Immunotherapy is changing the treatment of patients
with metastatic cancer and leads to a long-term response
in a subset of patients [7]. Immune checkpoint inhibitors
(ICIs), such as anti-CTLA4 and anti-PD-1/PD-L1 mole-
cules, are being used effectively in clinical practice.Correspondence: maria.rescigno@ieo.eu
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from an ineffective state that does not allow them to
respond to antigens. However, we do not know how
T cells are reactivated and what the characteristics of
the patients who respond are.Learning from mouse models
Vetizou et al. [1] and Sivan et al. [2] show that the effi-
or treated with antibiotics the ICIs lost their therapeutic
efficacy. In both studies, the authors found that, in the
presence of the microbiota, host antigen-presenting cells
activate interferon (IFN)γ-producing T cells, which are
enriched during ICI treatment. It is amazing that the
microbiota contributes to immune cell activation at dis-
tant sites and in particular tumor sites. The researchers
excluded the possibility that these effects occur through
systemic dissemination of the microbiota. This observa-
tion raises the question of whether microbial metabolites
disseminate systemically and reach tumor compartments
or whether these metabolites act on peripheral lymphoid
organs.
In the study by Vetizou et al. [1], the researchers iden-
tified several Bacteroides species, including Bacteroides
fragilis, and polysaccharide A produced by this bacter-
ium as capable of promoting the maturation of intratu-
moral dendritic cells and inducing type 1 helper T cells
in tumor-draining lymph nodes. Sivan et al. found that
wild-type C57BL/6 mice from two different providers,
the Jackson Laboratory (Jax) and Taconic (Tac), exhib-
ited significant differences in the rate of melanoma
growth, with tumors growing faster in Tac mice. The
same trend was observed when mice were treated with
anti-PD-L1, with a better response observed in Jax mice
than in Tac mice. The authors compared the microbiotas
of the mice housed in the two animal facilities and cor-
related their components with the amount of activated
antigen-presenting cells in the tumor microenvironment.
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associated with the amount of antigen-presenting cells
in tumors. Interestingly, administration of a mixture
of B. breve and B. longum to Tac mice resulted in im-
proved tumor control and increased IFNγ levels in
tumor-draining lymph nodes and spleen.
Microbial diversity and therapy outcome
These results indicate that having a ‘fit’ microbiota helps
the immune system to perform effective immune sur-
veillance. They also raise the questions of what a ‘fit’
microbiota is and how we can intervene to provide the
best microbiota to patients. As the diversity of the
microbiota is in part genetically determined [8], are
some individuals predisposed to have a less effective
microbiota, is the microbiota shaped during tumor
development, or are both of these statements true?
Interestingly, Vetizou et al. [1] show that administra-
tion of B. fragilis or Bacteroides thetaiotamicron to wild-
type mice can alter the activity of anti-CTLA4 in vivo,
and also reduce the inflammatory response initiated by
this antibody in the intestine. These findings indicate
that the right bacterial combination can both potentiate
the activity of ICIs and provide protection from the
adverse effects of therapy, thus ‘uncoupling’ efficacy and
toxicity of the antibody. The researchers also found that
administration of anti-CTLA4 modifies the microbiota
composition and increases the levels of the strains that
seem to have a beneficial antitumor effect. These
findings were paralleled by observations in patients with
metastatic melanoma who were treated with anti-
CTLA4. The researchers found that patients could be
divided into three groups according to their microbiota
(enterotypes) and that two enterotypes were associated
with a better outcome than the other enterotype. The
‘good’ enterotypes were enriched in some, but not other,
Bacteroides species that mediate the therapeutic effect of
the drug, whereas the ‘bad’ enterotype still had quite a
high number of B. fragilis, which potentiated the efficacy
of anti-CTLA4 in mice. These findings suggest that
either this species is effective only in the right micro-
bial context or that some individuals select strains of
B. fragilis that are more beneficial than others despite
belonging to the same species.
It is obvious that these studies have huge therapeutic
implications, but they also raise important issues. Can
we improve an individual’s microbiota to achieve
maximal therapeutic efficacy of immunotherapy? Is it
sufficient to administer one species, such as B. fragilis
or B. breve, or should we give a mixture of microor-
ganisms, or even perform fecal transplantation of the
microbiota? If two therapeutic options are available,
should we select or exclude them according to the
enterotype of the patient? As chemotherapy andcytokine-based immunotherapy also rely on the micro-
biota for their efficacy [9, 10], are there different entero-
types that mediate the response to different therapeutic
agents or are there enterotypes that favor any possible
therapy regardless of whether it is chemotherapy, im-
munotherapy or targeted therapy?
One thing is clear from these studies: the composition
of our microbiota should be considered in future clinical
studies aimed at assessing the therapeutic efficacy of
new anticancer agents.
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